Last reviewed · How we verify

loratadine; montelukast — Competitive Intelligence Brief

loratadine; montelukast (loratadine; montelukast) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histamine H1 antagonist, Leukotriene receptor antagonist. Area: Allergy, Asthma.

phase 3 Histamine H1 antagonist, Leukotriene receptor antagonist H1 receptor, CysLT1 receptor Allergy, Asthma Small molecule Live · refreshed every 30 min

Target snapshot

loratadine; montelukast (loratadine; montelukast) — Organon and Co. Loratadine is an antihistamine that blocks the action of histamine, a substance in the body that causes allergy symptoms, while montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, substances in the body that cause inflammation and constriction of airways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
loratadine; montelukast TARGET loratadine; montelukast Organon and Co phase 3 Histamine H1 antagonist, Leukotriene receptor antagonist H1 receptor, CysLT1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histamine H1 antagonist, Leukotriene receptor antagonist class)

  1. Organon and Co · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). loratadine; montelukast — Competitive Intelligence Brief. https://druglandscape.com/ci/loratadine-montelukast. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: